A Trial Evaluating Maintenance Therapy With Lamivudine (Epivir®) and Dolutegravir (Tivicay®) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple Highly Active Antiretroviral Therapy (HAART) (ANRS 167 Lamidol)

Inclusion Criteria: * HIV-1 infected patient * Age ≥ 18 years * CD4 cell count nadir \> 200/mm3 * Genotype on pre-HAART interpreted with the last version of the ANRS AC11 resistance group's algorithm which presents: * no major mutation on protease among: D30N, V32I, M46I/L, I47A/V, G48V, I50L/V, 154M/L, L76V, V82A/F/T/S, I84V, N88D/S, L90M,- no mutation on RT (except the mutation A98S if the patient is not infected by the virus subtype C), * no mutation on integrase (if the genotype is available), * First-line treatment with suppressive triple HAART (2 NRTI + either 1 PI/r, 1 NNRTI or 1 INI). The initial treatment may have changed a maximum of two times but only once for toxicity (changes such Epivir / Ziagen to Kivexa, are not considered as a change of treatment). However, treatment has to be unchanged in the last 6 months * Plasma HIV RNA ≤ 50 copies/mL for ≥ 2 years with at least 2 viral load determinations per year. Blips (HIV viral load between 50 and 200 copies/mL but ≤ 50 copies/mL on control sample) are allowed except in the last 6 months. The total number of blips must not exceed 3 in the last 2 years * Negative Hepatitis Bs Antigen * Effective contraception for women of childbearing potential * Informed consent form signed by patient and investigator * Patient enrolled in or a beneficiary of a Social Security programme (State Medical Aid ("Aide Médicale d'Etat" AME in France) is not a Social Security programme) Exclusion Criteria: * HIV-2 infection * Positive HBc Ac isolated * Hepatitis B Virus (HBV) co-infected patients (positive Hepatitis Bs Ag at inclusion) * Chronic hepatitis C currently treated or needing therapy in the next 12 months * History of HIV-associated neurocognitive disorders * Current pregnancy or breastfeeding * No effective contraception for the women of childbearing * Previous treatment with chemotherapy (except bleomycin on Kaposi disease's treatment) or immunotherapy * Grade \> 2 abnormality for usual biological parameters (liver function tests, blood cell count) * ALT(Alanine Aminotransferase) ≥ 5 x upper limit of normal value (ULN) or AST (Aspartate Aminotransferase) ≥ 3 x ULN and bilirubinemia ≥ 1.5 x ULN (with 35% direct bilirubinemia) * Unstable liver disease (ascitis, encephalopathy, coagulopathy, hypoalbuminemia, oesophageal or gastric varices or persistent jaundice) * Known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones) * Creatininemia clearance below 50 mL/min (Cockroft-Gault method) * History or presence of allergy to the trial drugs or their components * Severe hepatic insufficiency (Child Pugh Class C) * Patients participating in another clinical trial including an exclusion period that is still in force during the screening phase * Patients under "sauvegarde de justice" (judicial protection due to temporarily and slightly diminished mental or physical faculties) or under legal guardianship.